drugset / Trial / NCT02132299

Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults

NCT02132299

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This trial will evaluate whether relatively non-immune populations in endemic countries can effectively generate significant cellular and humoral immune responses that confer protection against P. falciparum infection after inoculation of aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) Plasmodium falciparum sporozoites (PfSPZ Vaccine) administered intravenously (IV).

Timeline

Start
2014-04
Primary completion
2015-07
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject PfSPZ Vaccine Vaccine 30000 unknown Intravenous
Subject PfSPZ Vaccine Vaccine 135000 unknown Intravenous
Subject PfSPZ Vaccine Vaccine 270000 unknown Intravenous